9-(2'-hydroxymethyl-1'-cyclobutyl)adenine | 130368-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(2'-hydroxymethyl-1'-cyclobutyl)adenine
• 英文别名: 9-(2-Hydroxymethyl-1-cyclobutyl)adenine；[2-(6-aminopurin-9-yl)cyclobutyl]methanol
• CAS: 130368-79-5
• 化学式: C₁₀H₁₃N₅O
• 分子量: 219.246
• InChiKey: CNCYBSHSXAUTJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  9-(2-methoxycarbonyl-1-cyclobutyl)adenine 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以97%的产率得到9-(2'-hydroxymethyl-1'-cyclobutyl)adenine
  参考文献：
  名称：

  Process for preparation of intermediates of carbocyclic nucleoside

  摘要：

  该化合物的化学式为：##STR1## 其中A是嘌呤-9-基团，嘌呤-9-基团的杂环同分异构体，嘧啶-1-基团或嘧啶-1-基团的杂环同分异构体；E是氢，-CH.sub.2 OH或-OH；G和D分别选择自氢，C.sub.1到C.sub.10烷基，-OH，-CH.sub.2 OH，-CH.sub.2 OR.sub.20，其中R.sub.20是C.sub.1到C.sub.6烷基，-CH.sub.2 OC(O)R.sub.21，其中R.sub.21是C.sub.1到C.sub.10烷基，-CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22是任何天然氨基酸的侧链，R.sub.23是氢或-C(O)CH(R.sub.24)(NH.sub.2)，其中R.sub.24是任何天然氨基酸的侧链，-CH.sub.1 SH，-Ch.sub.2 Cl，-Ch.sub.2 F，-CH.sub.2 Br，-CH.sub.2 I，-C(O)H，-CH.sub.2 CN，-CH.sub.2 N.sub.3，-CH.sub.2 NR.sub.1 R.sub.2，-CO.sub.2 R.sub.1，-CH.sub.2 CH.sub.2 OH，-CH.sub.2 CH.sub.2 OR.sub.20，其中R.sub.20如上定义，-CH.sub.2 CH.sub.2 OC(O)R.sub.21，其中R.sub.21如上定义，-CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22和R.sub.23如上定义，-CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2，-Ch.sub.2 OPO.sub.3 H.sub.2，-OCH.sub.2 PO.sub.3 H.sub.2和-CH.sub.2 CO.sub.2 R.sub.3，其中R.sub.1和R.sub.2分别选择自氢和C.sub.1到C.sub.10烷基，R.sub.3是氢，C.sub.1到C.sub.10烷基，羧基烷基或氨基烷基；或其药用可接受盐。

  公开号：

  US05153352A1

文献信息

• Carbocyclic nucleoside analogs
  申请人：Bristol-Myers Squibb Company

  公开号：US05246931A1

  公开（公告）日：1993-09-21

  A compound of the formula: ##STR1## wherein A is a purin-9-yl group, a heterocyclic isostere of a purin-9-yl group, a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; E is hydrogen, --CH.sub.2 OH or --OH; and G and D are independently selected from hydrogen, C.sub.1 to C.sub.10 alkyl, --OH, --CH.sub.2 OH, --CH.sub.2 OR.sub.20 wherein R.sub.20 is C.sub.1 to C.sub.6 alkyl, --CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is C.sub.1 to C.sub.10 alkyl, --CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 is the side chain of any of the naturally occurring amino acids and R.sub.23 is hydrogen or --C(O)CH(R.sub.24)(NH.sub.2) wherein a R.sub.24 is the side chain of any of the naturally occurring amino acids, --CH.sub.2 SH, --CH.sub.2 Cl, --CH.sub.2 F, --CH.sub.2 Br, --CH.sub.2 I, --C(O)H, --CH.sub.2 CN, --CH.sub.2 N.sub.3, --CH.sub.2 NR.sub.1 R.sub.2, --CO.sub.2 R.sub.1, --CH.sub.2 CH.sub.2 OH, --CH.sub.2 CH.sub.2 OR.sub.20 wherein R.sub.20 is as defined above, --CH.sub.2 CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is as defined above, --CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 and R.sub.23 are as defined above, --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2, --CH.sub.2 OPO.sub.3 H.sub.2, --OCH.sub.2 PO.sub.3 H.sub.2 and --CH.sub.2 CO.sub.2 R.sub.3 wherein R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 to C.sub.10 alkyl and R.sub.3 is hydrogen, C.sub.1 to C.sub.10 alkyl, carboxyalkyl or aminoalkyl; or a pharmaceutically acceptable salt thereof.

  该化合物的化学式为：##STR1## 其中A是嘌呤-9-基团，嘌呤-9-基团的杂环同分异构体，嘧啶-1-基团或嘧啶-1-基团的杂环同分异构体；E是氢，--CH.sub.2 OH或--OH；G和D独立地选择自氢，C.sub.1到C.sub.10烷基，--OH，--CH.sub.2 OH，--CH.sub.2 OR.sub.20，其中R.sub.20是C.sub.1到C.sub.6烷基，--CH.sub.2 OC（O）R.sub.21，其中R.sub.21是C.sub.1到C.sub.10烷基，--CH.sub.2 OC（O）CH（R.sub.22）（NHR.sub.23），其中R.sub.22是任何天然氨基酸的侧链，R.sub.23是氢或--C（O）CH（R.sub.24）（NH.sub.2），其中R.sub.24是任何天然氨基酸的侧链，--CH.sub.2 SH，--CH.sub.2 Cl，--CH.sub.2 F，--CH.sub.2 Br，--CH.sub.2 I，--C（O）H，--CH.sub.2 CN，--CH.sub.2 N.sub.3，--CH.sub.2 NR.sub.1 R.sub.2，--CO.sub.2 R.sub.1，--CH.sub.2 CH.sub.2 OH，--CH.sub.2 CH.sub.2 OR.sub.20，其中R.sub.20如上定义，--CH.sub.2 CH.sub.2 OC（O）R.sub.21，其中R.sub.21如上定义，--CH.sub.2 CH.sub.2 OC（O）CH（R.sub.22）（NHR.sub.23），其中R.sub.22和R.sub.23如上定义，--CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2，--CH.sub.2 OPO.sub.3 H.sub.2，--OCH.sub.2 PO.sub.3 H.sub.2和--CH.sub.2 CO.sub.2 R.sub.3，其中R.sub.1和R.sub.2独立地选择自氢和C.sub.1到C.sub.10烷基，R.sub.3是氢，C.sub.1到C.sub.10烷基，羧基烷基或氨基烷基；或其药学上可接受的盐。
• 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
  申请人：Liotta C. Dennis

  公开号：US20060223835A1

  公开（公告）日：2006-10-05

  Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.

  提供环丁基核苷和它们的使用方法，用于治疗感染，包括Retroviridae（包括HIV），Hepadnaviridae（包括HBV）或Flaviviridae（包括BVDV和HCV）感染，或与异常细胞增殖有关的病症，在宿主（包括动物，尤其是人类）中使用。
• 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation
  申请人：Liotta Dennis C.

  公开号：US20090149416A1

  公开（公告）日：2009-06-11

  Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.

  提供了环丁基核苷和它们的使用方法，用于治疗感染，包括逆转录病毒科（包括HIV），乙肝病毒科（包括HBV）或黄病毒科（包括BVDV和HCV）感染，或与异常细胞增殖有关的情况，在宿主中使用，包括动物，尤其是人类。
• 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：EMORY UNIVERSITY

  公开号：EP1828145A2

  公开（公告）日：2007-09-05
• EP1828145A4
  申请人：——

  公开号：EP1828145A4

  公开（公告）日：2009-08-19